Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jayson L Parker"'
Autor:
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 1955-1963 (2021)
Abstract Purpose To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. Methods Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non
Externí odkaz:
https://doaj.org/article/65ec00578e364bdfb9e9535663c41254
Publikováno v:
American Journal of Clinical Oncology. 46:58-65
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6febae5713fc94a4cddddf4745f4c984
https://doi.org/10.1097/coc.0000000000000963
https://doi.org/10.1097/coc.0000000000000963
Publikováno v:
The Oncologist. 27:849-856
Background The purpose of this study was to explore the effects biomarkers have on the duration and speed of clinical trials in oncology. Materials and Methods Clinical trial data was pooled from www.clinicaltrials.gov within the 4 cancer indications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0fc07ac3388b2425e258feb03cb2848
https://doi.org/10.1093/oncolo/oyac130
https://doi.org/10.1093/oncolo/oyac130
Autor:
Ashini Weerasinghe, Sebnem S. Kuzulugil, Kirill Pereverzev, Jayson L. Parker, Bora Caglayan, Stephen Mac, Daniel A. Rubinger, Nicholas Mitsakakis, Ayse Bener, Adam Falconi, Zain Shah, Rohan Tangri, Gilberto Lopes
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 1955-1963 (2021)
Cancer Medicine
Cancer Medicine
Purpose To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. Methods Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non‐small ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e1182f8e14ab1d2bf40538f129c3a5
https://doaj.org/article/65ec00578e364bdfb9e9535663c41254
https://doaj.org/article/65ec00578e364bdfb9e9535663c41254
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2016 (2016)
Background and Aims. This study analyzed the risk of clinical trial failure of new drugs for hepatitis C between January 1998 and January 2015. Methods. Hepatitis C drug development trials that were in phases I–III of clinical trial testing were ob
Externí odkaz:
https://doaj.org/article/30c690bb64734839a0709f469f45a18c
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 17, Iss 3 (2014)
Purpose. To determine the risk of clinical trial failure for drugs developed for type-2 diabetes. Methods. Drugs were investigated by reviewing phase I to phase III studies that were conducted between 1998 and February 2013. The clinical trial succes
Externí odkaz:
https://doaj.org/article/d71ad20fa85c48019d88ce3e5a8477b2
Publikováno v:
Hematological oncologyREFERENCES. 39(1)
This study analyzed the risk of clinical trial failure for leukemia drug development between January 1999 and January 2020. The specific leukemia subtypes of interest were acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute my
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866e5f9508b98bd32ec2f84dc9db114a
https://pubmed.ncbi.nlm.nih.gov/33078436
https://pubmed.ncbi.nlm.nih.gov/33078436
Publikováno v:
Expert Opinion on Therapeutic Patents. 26:871-875
This paper explores whether, and under what circumstances, a biosimilar approved in the United States under the Biologics Price Competition and Innovation Act (hereafter 'BPCIA') can be patented. The possibility that a biosimilar product could have m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048526086d5b6cd35b9c75055ea52ce5
https://doi.org/10.1080/13543776.2016.1193156
https://doi.org/10.1080/13543776.2016.1193156
Autor:
Abrar Alturkistani, Juanjuan An, Norbert Benda, Karina Bienfait, Adele R. Blackler, Martin Bøgsted, David Brindley, Karl Broich, Rasmus F. Brøndum, Patrick Brunhoeber, Matthew Bureau, Josip Car, Alison Carter, Tara Clarke, June Clements, Darren Cross, Brett Doble, Marisa Dolled-Filhart, Elena Domazetoski, Mark W. Duncan, Ehab A. ElGabry, Aaron R. Ellison, Kenneth Emancipator, Harald Enzmann, Maria Farooq, Janine Feng, Kimberley Foley, Evgenii Generalov, Ning Fei Go, Alexey Goltsov, George A. Green, Maria Hersom, Narimon Honarpour, Lahiru Iddamalgoda, Masayuki Ikeda, Suzanne Jenkins, Jan Trøst Jørgensen, Monesh Kapadia, Sylwia Karwowska, Sebnem S. Kuzulugil, Ching Lam, Jason S. Lewis, Jinbo Li, Oliver Liesenfeld, Gilberto Lopes, Dee Luo, Edward Meinert, Ralf Meyer, Amita Mistry, Nicholas Mitsakakis, Jens Mollerup, Michael C. Montalto, Lauren B. Murata, Muhammed Murtaza, Karsten Bork Nielsen, Saumya Pant, Jayson L. Parker, Patrícia M.R. Pereira, Manjunath Ramarao, Ted Rigl, Oliver Schildgen, Verena Schildgen, Catharina Scholl, Sidney A. Scudder, Donna Seyfried, Abha Sharma, Rumiko Shimazawa, Richard Simon, Shalini Singh, Nicholas B. Sobol, David A. Stanforth, Julia Stingl, Vijayaraghava Seshadri Sundararajan, Prashanth Suravajhala, Alessandra Tosolini, Jeff Tsou, Kathryn M. Tully, Eric E. Walk, Dianna Wu, Xiaolei Xu, Karen Yu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6486bed3732fa46213d3cbf9f5daccdf
https://doi.org/10.1016/b978-0-12-813539-6.00033-x
https://doi.org/10.1016/b978-0-12-813539-6.00033-x
